GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (FRA:XSQ) » Definitions » EV-to-EBITDA

SQI Diagnostics (FRA:XSQ) EV-to-EBITDA : -4.60 (As of May. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is SQI Diagnostics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SQI Diagnostics's enterprise value is €40.71 Mil. SQI Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was €-8.85 Mil. Therefore, SQI Diagnostics's EV-to-EBITDA for today is -4.60.

The historical rank and industry rank for SQI Diagnostics's EV-to-EBITDA or its related term are showing as below:

FRA:XSQ's EV-to-EBITDA is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 16.37
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), SQI Diagnostics's stock price is €0.093. SQI Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was €0.000. Therefore, SQI Diagnostics's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


SQI Diagnostics EV-to-EBITDA Historical Data

The historical data trend for SQI Diagnostics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQI Diagnostics EV-to-EBITDA Chart

SQI Diagnostics Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.31 -4.35 -11.43 -7.69 -4.95

SQI Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.17 -7.54 -4.95 -5.69 -3.42

Competitive Comparison of SQI Diagnostics's EV-to-EBITDA

For the Diagnostics & Research subindustry, SQI Diagnostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SQI Diagnostics's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SQI Diagnostics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where SQI Diagnostics's EV-to-EBITDA falls into.



SQI Diagnostics EV-to-EBITDA Calculation

SQI Diagnostics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=40.708/-8.849
=-4.60

SQI Diagnostics's current Enterprise Value is €40.71 Mil.
SQI Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SQI Diagnostics  (FRA:XSQ) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

SQI Diagnostics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.093/0.000
=N/A

SQI Diagnostics's share price for today is €0.093.
SQI Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


SQI Diagnostics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of SQI Diagnostics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


SQI Diagnostics (FRA:XSQ) Business Description

Traded in Other Exchanges
N/A
Address
36 Meteor Drive, Toronto, ON, CAN, M9W 1A4
SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.

SQI Diagnostics (FRA:XSQ) Headlines

No Headlines